Tocilizumab doesn't ease symptoms or prevent death in moderately ill COVID-19 inpatients

https://www.eurekalert.org/pub_releases/2020-10/mgh-tde102020.php

News Release 21-Oct-2020
Massachusetts General Hospital

The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a new study led by researchers at Massachusetts General Hospital (MGH). The study, published in the New England Journal of Medicine (NEJM), casts doubt on earlier research suggesting that tocilizumab, which is commonly prescribed for rheumatoid arthritis (RA) and other conditions, might be an effective treatment for patients with worsening cases of COVID-19.


•••••